Vericel (NASDAQ:VCEL) Insider Jonathan Siegal Sells 2,732 Shares

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Siegal sold 2,732 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $44.90, for a total transaction of $122,666.80. Following the completion of the transaction, the insider directly owned 886 shares in the company, valued at $39,781.40. This represents a 75.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Vericel Stock Down 1.3%

Shares of NASDAQ:VCEL opened at $44.49 on Wednesday. Vericel Corporation has a fifty-two week low of $28.95 and a fifty-two week high of $46.62. The firm’s 50-day simple moving average is $36.51 and its 200-day simple moving average is $35.90. The company has a market cap of $2.27 billion, a price-to-earnings ratio of 105.93 and a beta of 1.12.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The firm had revenue of $68.43 million during the quarter, compared to the consensus estimate of $63.68 million. During the same quarter last year, the firm earned ($0.23) earnings per share. The firm’s revenue was up 30.1% compared to the same quarter last year. On average, research analysts forecast that Vericel Corporation will post 0.49 EPS for the current year.

Institutional Investors Weigh In On Vericel

A number of large investors have recently added to or reduced their stakes in the business. Huntington National Bank lifted its holdings in shares of Vericel by 51.3% in the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 273 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Vericel by 1.4% in the 4th quarter. State of Alaska Department of Revenue now owns 25,744 shares of the biotechnology company’s stock valued at $927,000 after buying an additional 353 shares in the last quarter. Osaic Holdings Inc. grew its holdings in Vericel by 13.7% during the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 353 shares during the last quarter. California State Teachers Retirement System increased its position in Vericel by 0.8% during the second quarter. California State Teachers Retirement System now owns 45,404 shares of the biotechnology company’s stock worth $1,932,000 after buying an additional 382 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in shares of Vericel by 3.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 11,698 shares of the biotechnology company’s stock worth $421,000 after acquiring an additional 410 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts recently weighed in on VCEL shares. Leerink Partners restated an “outperform” rating and issued a $46.00 price target on shares of Vericel in a research note on Tuesday, March 10th. Weiss Ratings raised Vericel from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Wall Street Zen cut shares of Vericel from a “buy” rating to a “hold” rating in a research note on Sunday, June 14th. Truist Financial reduced their price objective on shares of Vericel from $48.00 to $42.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Finally, HC Wainwright restated a “buy” rating and set a $64.00 target price on shares of Vericel in a research report on Friday, May 8th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vericel presently has a consensus rating of “Hold” and an average price target of $52.50.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.